Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: December 14, 2017
Event Date: December 8, 2017
Context: The Company is an emerging growth company reporting the termination of a material definitive agreement with BioDelivery Sciences International, Inc. (BDSI).
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Termination of Agreement: On December 8, 2017, Collegium provided written notice to BDSI to terminate the License and Development Agreement dated May 11, 2016.
- Effective Date: The termination will become effective on March 8, 2018.
- Asset Reversion: Upon termination, Collegium's rights to develop and commercialize Onsolis (fentanyl buccal soluble film) will revert to BDSI.
- Strategic Rationale: The decision follows a review of the product portfolio in connection with a new license agreement with Depomed to commercialize Nucynta (tapentadol) Immediate Release and Nucynta ER in the U.S.
Guidance, Outlook, and Risks
Outlook: The Company expects to license the right to commercialize Nucynta products in the U.S. through its agreement with Depomed.
Risks/Contingencies: The primary contingency is the loss of rights to Onsolis effective March 8, 2018, as the agreement terminates. The filing references the full text of the terminated agreement for detailed terms but does not disclose specific financial penalties or litigation risks within this text.
Key Facts for Investor Verification
- Verify the terms and financial impact of the new license agreement with Depomed regarding Nucynta.
- Confirm the exact date (March 8, 2018) when rights to Onsolis revert to BDSI.
- Review the May 12, 2016 Form 8-K and August 11, 2016 Form 10-Q for the original material terms of the terminated BDSI agreement.
- Assess the strategic shift from the Onsolis portfolio to the Nucynta portfolio.